Biomerica Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.75+0.05 (+1.85%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close2.70
Bid0.00 x
Ask0.00 x
Day's Range2.65 - 2.82
52wk Range1.41 - 3.38
1y Target EstN/A
Market Cap22.51M
P/E Ratio (ttm)-13.96
Avg Vol (3m)12,750
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research5 days ago

    BMRA: Base Business Bounces Back, InFoods Continues To Attract Who’s-Who of IBS

    Q1 2017 Results / Operational Update: Base Business Bounces Back, InFoods Supported by IBS ‘Dream Team’... BMRA is moving further towards the possibility of bringing their IBS test to market.  In early calendar 2015 the company filed the first set of patents related to the product.  In March the company announced that their international method and composition patent claims were reviewed by the International Search Authority (ISA) which found them to be novel and non-obvious.  Locking down the IP will be an important initial step.  Currently 17 patents are pending.  In June 2016 the international patent bureau effected an application communication date of May, 19 2016.  Additional details regarding the specific test-related methodology is included in the patent application as are examples of how InFoods’ methodology differs from prior art (in our opinion prior art is somewhat surprisingly lacking in robustness of statistical and other scientific methodology in regards to identification of IBS-related trigger foods).

  • Biomerica, Inc. :BMRA-US: Earnings Analysis: Q1, 2017 By the Numbers : October 19, 2016
    Capital Cube6 days ago

    Biomerica, Inc. :BMRA-US: Earnings Analysis: Q1, 2017 By the Numbers : October 19, 2016

    Categories: Yahoo Finance Get free summary analysis Biomerica, Inc. reports financial results for the quarter ended August 31, 2016. Highlights Summary numbers: Revenues of USD 1.41 million, Net Earnings of USD -0.06 million. Gross margins widened from 32.74% to 40.92% compared to the same period last year, operating (EBITDA) margins now -0.90% from -1.35%. Change in operating cash ... Read more (Read more...)

  • Marketwired7 days ago

    Biomerica Announces First Quarter Fiscal 2017 Financial Results, Sales Increase Over Prior Year

    Biomerica, Inc. , a global provider of advanced diagnostic products, today reported net sales of $1,410,110 for the three months ending August 31, 2016, compared to $1,286,993 for the same period in the ...